Seelos Therapeutics Receives a Notice of Allowance in Japan for SLS-005 (Trehalose)
Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced that it has received a Notice of Allowance from the Japanese Patent Office for its drug SLS-005.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced that it has received a Notice of Allowance from the Japanese Patent Office for its drug SLS-005. This patent, covering Japanese patent number 2016-512480, facilitates the treatment of oculopharyngeal muscular dystrophy (OPMD) using trehalose, administered intravenously. Trehalose is a disaccharide that crosses the blood-brain barrier, stabilizes proteins, and activates autophagy, potentially reducing protein aggregation in various diseases. This development marks a significant step in Seelos's efforts to address central nervous system disorders.
Positive
- Received Notice of Allowance for SLS-005 from Japanese Patent Office.
- Patent covers treatment for oculopharyngeal muscular dystrophy (OPMD) with trehalose.
- Trehalose shows potential in stabilizing proteins and activating autophagy.
Negative
- None.
Details
News Market Reaction – SEEL
The recorded move for SEEL in the trading session of this news was +19.35%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Jan. 22, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received a Notice of Allowance from the Japanese Patent Office (Japanese patent number 2016-512480) covering SLS-005 titled: "Treatment of Protein Aggregation Myopathic and Neurodegenerative Diseases by Parenteral Administration of Trehalose".
The allowed claims cover a pharmaceutical formulation comprised of trehalose for use in a method for treating or alleviating oculopharyngeal muscular dystrophy (OPMD) in a human subject. The allowed claims cover a method comprised of an intravenous administration of a therapeutically effective amount of a pharmaceutical formulation, with trehalose as the sole active ingredient, that complies with other parameters regarding the formulation characteristics and duration of intravenous administration, as described in the patent application.
About Trehalose
Trehalose is a low molecular weight disaccharide (0.342 kDa) that crosses the blood brain barrier, stabilizes proteins, and importantly activates autophagy which is the process that clears material from cells. In several animal models of diseases, associated with abnormal cellular protein aggregation or storage of pathologic material, it has been shown to reduce aggregation of misfolded proteins and reduce accumulation of pathologic material. Trehalose activates autophagy through the activation of Transcription Factor EB (TFEB), a key factor in lysosomal and autophagy gene expression. Activation of TFEB is an emerging therapeutic target for a number of diseases with pathologic accumulation of storage material.
Contact Information
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
View original content to download multimedia:http://www.prnewswire.com/news-releases/seelos-therapeutics-receives-a-notice-of-allowance-in-japan-for-sls-005-trehalose-301212973.html
SOURCE Seelos Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.